icon-folder.gif   Conference Reports for NATAP  
 
  International Symposium on Viral Hepatitis and Liver Disease
March 20th - 24th 2009
Washington, DC
Back grey_arrow_rt.gif
 
 
 
Telaprevir (TVR, T) q8h or q12h Combined With Either Peginterferon (PEG-IFN, P) Alfa-2a or Alfa-2b and Ribavirin (RBV, R) in Treatment-NaÔve Genotype 1 Hepatitis C: Week 12 Interim Results of the Randomized, Open-Label, Multicenter Phase 2 Study C208
 
 
  Reported by Jules Levin
13th ISVHLD Wash DC March 20-24 2009
 
Xavier Forns,1 Patrick Marcellin,2 Tobias Goser,3 Peter Ferenci,4 Frederik Nevens,5 Giampiero Carosi,6 Joost P, Drenth,7 Katrien De Backer,8 Rolf van Heeswijk,8 Els De Paepe,8 Gaston Picchio,9 Maria Beumont-Mauviel8 1 Liver Unit, University of Barcelona, Barcelona, Spain; 2 Hopital Beaujon, Clichy, France; 3 Klinikum der Universitšt zu Koln, Koln, Germany; 4 Department of Internal Medicine, Medical University of Vienna, Vienna, Austria; 5 Department of Hepatology, University Hospital Gasthuisberg, Leuven, Belgium; 6 Clinic of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy; 7 Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; 8 Tibotec BVBA, Mechelen, Belgium; 9 Tibotec Inc., Yardley, PA, USA.

Conducted-1.gif

method-2.gif

OtherAss-3.gif

Trugene-4.gif

itt-5.gif

undectable-6.gif

treatment-7.gif

Rash-8.gif

pharm-9.gif

summary-10.gif